April 21, 2022

Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, in patients of all ages. It was previously approved for this use only in adults.

  • First FDA approved in 2014, Zerbaxa is also indicated to treat adults who have hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
  • Recommended dosing and the duration of treatment are based on factors such as the patient’s age, weight, renal health, and diagnosis.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More